Skip to main content

Table 4 Review of literature on SBRT

From: Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma

Authors Study Localization Nr. of Lesions Nr. of Fractions Total Dose (Gy) LC @ 1 year Median OS (months) Late Toxicity
Tse [34] P IHCC
EHCC
10
0
6 28-48 65% 15 1 biliary obstruction
1 bowel obstruction
Goodman [29] P IHCC
EHCC
5
0
1 18-30 77% 28.6 None
Polistina [28] R IHCC
EHCC
0
10
3 30a 80%b 35.5 1 ulceration
2 stenosis
Ibarra [35] R IHCC
EHCC
11
0
3 22-50 55.5% 11 3 Grad 3
Barney [36] R IHCC
EHCC
6
4
3-5 45-60 100% 15.5 1 Grade 3 biliary stenosis, 1 Grade 5 liver failure
Momm [22] R IHCC
EHCC
0
13
10-12 32-56 78% 33.5 1 Grade 3
5 cholangitis
Weiner [37] P IHCC
EHCC
12
0
5 40-55 91%§ 13.2 1 hepatic failure§
1 biliary stricture
Kopek [27] R IHCC
EHCC
26
1
3 45 85% 10.6 6 ulcerations
3 stenosis
Mahadevan [30] R IHCC
EHCC
31
11
3-5 24-45 88% 17 4 Grade 3 (ulceration, cholangitis, abscess)
Sandler [26] R IHCC
EHCC
6
25
5 40 78% 15.7 5 Grade ≥ 3
Jung [25] R IHCC
EHCC
33
25±
1-5 15-60 85% 10 6 Grade 3 (ulceration, cholangitis, stenosis, perforation)
Current R IHCC
EHCC
17
26
3-12 21-66 78% 14 3 Grade ≥ 3
  1. R retrospective, P prospective, IHCCC intrahepatic cholangiocarcinoma, EHCCC extrahepatic cholangiocarcinoma
  2. aconcurrent Gemcitabine
  3. blocal response ratio
  4. ± 5 patients treated with conventional fractionation with a stereotactic boost
  5. §In this study SBRT was performed also in patients with hepatocellular carcinoma. LC and toxicities are reported for the whole group of patients including hepatocellular and cholangiocarcinoma